{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:34:40Z","timestamp":1790213680646,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006343","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T00:00:00Z","timestamp":1266364800000}}],"reference-count":77,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006343.pub2","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T14:30:39Z","timestamp":1266417039000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections"],"prefix":"10.1002","volume":"2015","author":[{"given":"Christopher C","family":"Blyth","sequence":"first","affiliation":[{"name":"University of Western Australia; School of Paediatrics and Child Health; Princess Margaret Hospital Roberts Road Subiaco WA Australia 6008"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hale","sequence":"additional","affiliation":[{"name":"Children's Hospital at Westmead; Department of Allergy, Immunology & Infectious Diseases; Westmead New South Wales Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Palasanthiran","sequence":"additional","affiliation":[{"name":"Sydney Children's Hospital; Department of Immunology and Infectious Diseases; High Street Randwick New South Wales Australia 2031"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Sydney Children's Hospital; Centre for Children's Cancer & Blood Disorders; High Street Randwick New South Wales Australia 2031"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Bennett","sequence":"additional","affiliation":[{"name":"Prince of Wales Clinical School, University of NSW; Department of Anaesthesia; Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,17]]},"reference":[{"key":"10.1002\/14651858.CD006343.pub2-BIB0001|cit1","unstructured":"Maertens J Madero L Reilly A Lehrnbecher T Groll A Jafri H A randomized, double blind, multicenter trial of caspofungin (CAS) versus (vs) liposomal amphotericin B (LAMB) for empirical antifungal therapy (EAFRx) of pediatric patients (pts) with persistent fever & neutropenia (PFN) Program and abstracts of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA [Abstract M-621] 2007 Sept"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.PCC.0000144712.29127.81","article-title":"Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study","volume":"5","author":"Mondal","year":"2004","journal-title":"Pediatric Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006343.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD006343.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"820-6","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: Substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"3","key":"10.1002\/14651858.CD006343.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children","volume":"22","author":"Sandler","year":"2000","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006343.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006343.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0008|cit8","unstructured":"Arrieta AC Telles Filho F Berezin E Freire A Diekmann-Berndt H A randomized, double-blind trial comparing micafungin (MCFG) and liposomal amphotericin B (L-AMB) in pediatric patients with invasive candidiasis. Program and abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco USA [Abstract M-1308b] 2006 Sept"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Arrieta A Queiroz-Telles F Berezin E Freire A Diekmann S Koblinger S Micafungin versus liposomal amphotericin B (AmBisome\u00ae) in paediatric patients with invasive candidiasis or candidaemia Program and abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases. Munich, Germany [Abstract O141] 2007 April","DOI":"10.1016\/S0924-8579(07)70091-2"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0010|cit10","first-page":"662","article-title":"Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection","volume":"50","author":"Bodhe","year":"2002","journal-title":"Journal of the Association of Physicians India"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006343.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD006343.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/00006454-199612000-00011","article-title":"Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial","volume":"15","author":"Driessen","year":"1996","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"2","key":"10.1002\/14651858.CD006343.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0163-4453(95)80009-3","article-title":"Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever-preliminary observations from a pilot, exploratory study","volume":"30","author":"Ellis","year":"1995","journal-title":"Journal of Infection"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006343.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-133-9-200011070-00009","article-title":"Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group","volume":"133","author":"Galgiani","year":"2000","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0018|cit18","unstructured":"Khayat N Amsallem D Nerich V Coquet F Leroy J Plouvier E Caspofungin versus liposomal amphotericin B for empirical therapy in children with persistently febrile neutropenia Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA [Abstract G-939] 2005 Dec"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Kim SY Park JS Jeong NG Jeong DC Cho B Kim HW Amphotericin B and itraconazole as empirical antifungal therapy in children with acute leukemia with neutropenic fever Program and abstracts of the 47th American Society of Hematology Meeting. Atlanta. USA [abstract - not selected for publication] 2005 Dec","DOI":"10.1182\/blood.V106.11.4577.4577"},{"issue":"9495","key":"10.1002\/14651858.CD006343.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"American Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD006343.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/mmy.40.4.411.417","article-title":"Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis","volume":"40","author":"Shikanai-Yasuda","year":"2002","journal-title":"Medical Mycology"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0959-8049(95)00619-2","article-title":"Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial","volume":"32A","author":"Viscoli","year":"1996","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0026|cit26","first-page":"316","article-title":"Comparison of caspofungin and liposomal amphotericin B for empirical antifungal therapy in patients with hematologic disease","volume":"32","author":"Wang","year":"2007","journal-title":"Chinese Journal of Antibiotics"},{"issue":"8","key":"10.1002\/14651858.CD006343.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1128\/AAC.45.8.2354-2357.2001","article-title":"Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole","volume":"45","author":"Wheat","year":"2001","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clinical infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006343.pub2-BIB0030|cit30","first-page":"178","article-title":"Antifungal therapy for treatment of cryptococcal meningitis","volume":"113","author":"Yao","year":"2000","journal-title":"Chinese Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1086\/367839","article-title":"Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients","volume":"36 Suppl 3","author":"Bennett","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD006343.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/AAC.33.11.1989","article-title":"Pharmacokinetics of amphotericin B in children","volume":"33","author":"Benson","year":"1989","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1542\/peds.2008-2055","article-title":"Not just little adults: candidemia epidemiology, molecular characterization and antifungal susceptibility in neonatal and pediatric patients","volume":"123","author":"Blyth","year":"2009","journal-title":"Paediatrics"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01974613","article-title":"Pharmacokinetics of fluconazole in pediatric patients","volume":"13","author":"Brammer","year":"1994","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0037|cit37","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003953.pub2","article-title":"Systemic antifungal drugs for invasive fungal infection in preterm infants","author":"Clerihew","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD006343.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad Trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-3062.2006.00127.x","article-title":"Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study","volume":"8","author":"Pauw","year":"2006","journal-title":"Transplant Infectious Disease"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Pauw","year":"2008","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD006343.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1705113","article-title":"Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation","volume":"36","author":"Dvorak","year":"2005","journal-title":"Bone Marrow Transplantation"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD006343.pub2-BIB0043|cit43","first-page":"668","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006343.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Reviews of Infectious Diseases"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10096-005-0080-0","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis","volume":"25","author":"Girois","year":"2006","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2008.06.040","article-title":"Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis","volume":"44","author":"Goldberg","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","article-title":"Trends in the postmortem epidemiology of invasive fungal infections at a university hospital","volume":"33","author":"Groll","year":"1996","journal-title":"Journal of Infection"},{"issue":"7-8","key":"10.1002\/14651858.CD006343.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1439-0507.1999.00496.x","article-title":"Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival","volume":"42","author":"Groll","year":"1999","journal-title":"Mycoses"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0050|cit50","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions version 5.0.0 (updated September 2009) Cochrane Collaboration 2009"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"2. Art No.: CD0","key":"10.1002\/14651858.CD006343.pub2-BIB0052|cit52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000969","article-title":"Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia","author":"Johansen","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Art No.: CD00","key":"10.1002\/14651858.CD006343.pub2-BIB0053|cit53","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000239","article-title":"Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients","author":"Johansen","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006343.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006343.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD006343.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clinical Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clinical Infectious Diseases"},{"issue":"16","key":"10.1002\/14651858.CD006343.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD006343.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/CMR.18.1.163-194.2005","article-title":"Combination treatment of invasive fungal infections","volume":"18","author":"Mukherjee","year":"2005","journal-title":"Clinical Microbiology Reviews"},{"issue":"10","key":"10.1002\/14651858.CD006343.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/503428","article-title":"A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis","volume":"42","author":"Pachl","year":"2006","journal-title":"Clinical Infectious Diseases"},{"issue":"24","key":"10.1002\/14651858.CD006343.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006343.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD006343.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD006343.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006343.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed","volume":"31","author":"Robinson","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD006343.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.mph.0000155861.38641.ca","article-title":"Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution","volume":"27","author":"Rosen","year":"2005","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006343.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.inf.0000157218.37603.84","article-title":"Pediatric aspergillosis: disease and treatment differences in children","volume":"24","author":"Steinbach","year":"2005","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/01.qco.0000185986.64759.9a","article-title":"New antifungal agents under development in children and neonates","volume":"18","author":"Steinbach","year":"2005","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006343.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD006343.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006343.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"11","key":"10.1002\/14651858.CD006343.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD006343.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"American Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006343.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:33:28Z","timestamp":1697279608000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006343.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,2,17]]},"references-count":77,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006343.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,17]]}}}